He who pays the piper calls the tune: the role of the industry sponsor in acute stroke trials.
Ischemic stroke remains a complex neurobiological and clinical disease, and stroke drug development remains time consuming and costly. In addressing these challenges, the pharmaceutical industry has a principal responsibility to ensure that the acute stroke trials it sponsors are ethically conducted, scientifically sound and satisfy global regulatory requirements. The industry must also be a leader in promoting the innovative and effective partnerships between the public, private and academic sectors that are necessary if new therapies for patients with acute stroke are to be developed.
Bozik
Michael
M
Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, N.J. 08540, USA. michael.bozik@bms.com
D000208:Acute Disease; D002986:Clinical Trials as Topic / Q000941:ethics* / Q000592:standards*; D004345:Drug Industry / Q000592:standards*; D006801:Humans; D020521:Stroke / Q000188:drug therapy*